Anti-factor xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis

Obstetrics and Gynecology

Volumn 112, Issue 4, 2008, Pages 884-889

  Fox, Nathan S ^a   Laughon, S Katherine ^b   Bender, Samuel D ^b   Saltzman, Daniel H ^b   Rebarber, Andrei ^b  

^a Maternal Fetal Medicine Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A ANTIBODY; DALTEPARIN; ENOXAPARIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; ANTITHROMBIN III;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL WEIGHT; OBESITY; PREGNANCY; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; MIDDLE AGED; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; ANTICOAGULANTS; ANTITHROMBIN III; BODY MASS INDEX; BODY WEIGHT; DALTEPARIN; ENOXAPARIN; FEMALE; GESTATIONAL AGE; HUMANS; LINEAR MODELS; MATERNAL AGE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 55449127268     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31818638dc     Document Type: Article

References (21)

1. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002;99: 333-41.
2. American College of Obstetricians and Gynecologists. Throm-boembolism in pregnancy. ACOG Practice Bulletin No. 19. Washington (DC): ACOG; 2000.
3. Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337:688-98.
4. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996;65:171-4.
5. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
6. Ellison J, Walker ID, Greer IA. Antenatal use of Enoxaparin for the prevention and treatment of thromboembolism during pregnancy. BJOG 2000;107:1116-21.
7. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062-8.
8. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87:380-3.
9. Rasmussen C, Wadt B, Jacobsen B. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int J Gynaecol Obstet 1994;47:121-5.
10. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001;108:1134-40.
11. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, et al. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007;98:1237-45.
12. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous throm-boembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197:457.e1-21.
13. Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003;101:1307-11.
14. Gyamfi C, Cohen R, Desancho MT, Gaddipati S. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. J Matern Fetal Neonatal Med 2005;18: 329-31.
15. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977;10:399-410.
16. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:627S-44S.
17. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.
18. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999;104: 230-40.
19. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S.
20. Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008;18:162-6.
21. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-31.